ePrints

Histone modifying enzymes as targets for therapeutic intervention in oesophageal adenocarcinoma

Lookup NU author(s): Dr Stella Breininger

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© 2021 by the authors. Licensee MDPI, Basel, Switzerland.Oesophageal adenocarcinoma (OAC) has a dismal prognosis, where curable disease occurs in less than 40% of patients, and many of those with incurable disease survive for less than a year from diagnosis. Despite the widespread use of systematic chemotherapy in OAC treatment, many patients receive no benefit. New treatments are urgently needed for OAC patients. There is an emerging interest in epigenetic regulators in cancer pathogenesis, which are now translating into novel cancer therapeutic strategies. Histone‐modifying enzymes (HMEs) are key epigenetic regulators responsible for dynamic covalent histone modifications that play roles in both normal and dysregulated cellular processes including tumorigenesis. Several HME inhibitors are in clinical use for haematological malignancies and sarcomas, with numerous on‐going clinical trials for their use in solid tumours. This review discusses the current literature surrounding HMEs in OAC pathogenesis and their potential use in targeted therapies for this disease.

Publication metadata

Author(s): Pickering OJ, Breininger SP, Underwood TJ, Walters ZS

Publication type: Review

Publication status: Published

Journal: Cancers

Year: 2021

Volume: 13

Issue: 16

Online publication date: 13/08/2021

Acceptance date: 10/08/2021

ISSN (electronic): 2072-6694

Publisher: MDPI

URL: https://doi.org/10.3390/cancers13164084

DOI: 10.3390/cancers13164084

Share